Smaller sized doses for perioral treatment than for higher facial purposes are utilised given that the oral musculature responds more strongly to a similar BTX-A dosing. Just one planning of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole indication and FDA approval lies in